Literature DB >> 23667257

Direct expression and validation of phage-selected peptide variants in mammalian cells.

Brian D Quinlan1, Matthew R Gardner, Vinita R Joshi, Jessica J Chiang, Michael Farzan.   

Abstract

Phage display is a key technology for the identification and maturation of high affinity peptides, antibodies, and other proteins. However, limitations of bacterial expression restrict the range and sensitivity of assays that can be used to evaluate phage-selected variants. To address this problem, selected genes are typically transferred to mammalian expression vectors, a major rate-limiting step in the iterative improvement of peptides and proteins. Here we describe a system that combines phage display and efficient mammalian expression in a single vector, pDQ1. This system permits immediate expression of phage-selected genes as IgG1-Fc fusions in mammalian cells, facilitating the rapid, sensitive characterization of a large number of library outputs for their biochemical and functional properties. We demonstrate the utility of this system by improving the ability of a CD4-mimetic peptide to bind the HIV-1 envelope glycoprotein and neutralize HIV-1 entry. We further improved the potency of the resulting peptide, CD4mim6, by limiting its ability to induce the CD4-bound conformation of the envelope glycoprotein. Thus, CD4mim6 and its variants can be used to investigate the properties of the HIV-1 envelope glycoprotein, and pDQ1 can accelerate the discovery of new peptides and proteins through phage display.

Entities:  

Keywords:  Antimicrobial Peptides; Antiviral Agents; Fc Fusion Protein; HIV-1; Human Immunodeficiency Virus; Immunoadhesin; Phage Display

Mesh:

Substances:

Year:  2013        PMID: 23667257      PMCID: PMC3696656          DOI: 10.1074/jbc.M113.452839

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5.

Authors:  T Mirzabekov; H Kontos; M Farzan; W Marasco; J Sodroski
Journal:  Nat Biotechnol       Date:  2000-06       Impact factor: 54.908

2.  Phage display for selection of novel binding peptides.

Authors:  S S Sidhu; H B Lowman; B C Cunningham; J A Wells
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

3.  Improved prediction of signal peptides: SignalP 3.0.

Authors:  Jannick Dyrløv Bendtsen; Henrik Nielsen; Gunnar von Heijne; Søren Brunak
Journal:  J Mol Biol       Date:  2004-07-16       Impact factor: 5.469

4.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site.

Authors:  C F Barbas; A S Kang; R A Lerner; S J Benkovic
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

5.  Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.

Authors:  Loïc Martin; François Stricher; Dorothée Missé; Francesca Sironi; Martine Pugnière; Philippe Barthe; Rafael Prado-Gotor; Isabelle Freulon; Xavier Magne; Christian Roumestand; André Ménez; Paolo Lusso; Francisco Veas; Claudio Vita
Journal:  Nat Biotechnol       Date:  2002-12-16       Impact factor: 54.908

6.  Expression and characterization of human CD4:immunoglobulin fusion proteins.

Authors:  G Zettlmeissl; J P Gregersen; J M Duport; S Mehdi; G Reiner; B Seed
Journal:  DNA Cell Biol       Date:  1990-06       Impact factor: 3.311

7.  Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1.

Authors:  K Ray; M J Embleton; B L Jailkhani; M K Bhan; R Kumar
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

8.  Prediction of human mRNA donor and acceptor sites from the DNA sequence.

Authors:  S Brunak; J Engelbrecht; S Knudsen
Journal:  J Mol Biol       Date:  1991-07-05       Impact factor: 5.469

9.  Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.

Authors:  Jianhua Sui; Wenhui Li; Akikazu Murakami; Azaibi Tamin; Leslie J Matthews; Swee Kee Wong; Michael J Moore; Aimee St Clair Tallarico; Mobolaji Olurinde; Hyeryun Choe; Larry J Anderson; William J Bellini; Michael Farzan; Wayne A Marasco
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

10.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

View more
  8 in total

1.  A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120.

Authors:  Brian D Quinlan; Vinita R Joshi; Matthew R Gardner; Kourosh H Ebrahimi; Michael Farzan
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

2.  A phage-displayed single-chain Fab library optimized for rapid production of single-chain IgGs.

Authors:  Rachel Hanna; Lia Cardarelli; Nish Patel; Levi L Blazer; Jarrett J Adams; Sachdev S Sidhu
Journal:  Protein Sci       Date:  2020-09-15       Impact factor: 6.725

3.  pMINERVA: A donor-acceptor system for the in vivo recombineering of scFv into IgG molecules.

Authors:  M Batonick; M M Kiss; E P Fuller; C M Magadan; E G Holland; Q Zhao; D Wang; B K Kay; M P Weiner
Journal:  J Immunol Methods       Date:  2016-02-03       Impact factor: 2.303

4.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Authors:  Matthew R Gardner; Lisa M Kattenhorn; Hema R Kondur; Markus von Schaewen; Tatyana Dorfman; Jessica J Chiang; Kevin G Haworth; Julie M Decker; Michael D Alpert; Charles C Bailey; Ernest S Neale; Christoph H Fellinger; Vinita R Joshi; Sebastian P Fuchs; Jose M Martinez-Navio; Brian D Quinlan; Annie Y Yao; Hugo Mouquet; Jason Gorman; Baoshan Zhang; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton; Peter D Kwong; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers; David T Evans; Beatrice H Hahn; Alexander Ploss; Paula M Cannon; Michael S Seaman; Michael Farzan
Journal:  Nature       Date:  2015-02-18       Impact factor: 49.962

Review 5.  Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.

Authors:  Matthew R Gardner; Michael Farzan
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

6.  eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients.

Authors:  Meredith E Davis-Gardner; Matthew R Gardner; Barnett Alfant; Michael Farzan
Journal:  PLoS Pathog       Date:  2017-12-18       Impact factor: 6.823

7.  Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.

Authors:  Yuka Otsuka; Kimberly Schmitt; Brian D Quinlan; Matthew R Gardner; Barnett Alfant; Adrian Reich; Michael Farzan; Hyeryun Choe
Journal:  PLoS Pathog       Date:  2018-08-20       Impact factor: 6.823

8.  In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25.

Authors:  Yiming Yin; Brian D Quinlan; Tianling Ou; Yan Guo; Wenhui He; Michael Farzan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-20       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.